This film just can't get a break. It's almost like... cursed or something.
NYS Entity Status
NYS Filing Date
JULY 10, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - NUWAVE PHARMA SERVICES INC
Around the Web
- ‘Amityville: The Awakening’ Is Finally Being Released… For Free
By Caleb Reading - Friday Sep 22, 2017
- Amid Opioid Crisis, Insurers Restrict Pricey, Less Addictive Painkillers
By KATIE THOMAS and CHARLES ORNSTEIN - Monday Sep 18, 2017
Drug companies and doctors have been accused of fueling the opioid crisis, but some question whether insurers have played a role, too.
- Publisher Tronc acquires Daily News, storied NY tabloid
By JENNIFER PELTZ, Associated Press - Monday Sep 4, 2017
NEW YORK (AP) — Newspaper publisher Tronc has acquired the Daily News, a storied New York tabloid newspaper that won a Pulitzer Prize this year but has been buffeted by the changing media environment.Chicago-based Tronc Inc., the publisher of the Los Angeles Times and the Chicago Tribune, announced the deal Monday night, and the Daily News posted a story on its website.Tronc CEO Justin Dearborn said acquiring the paper and its popular website would "provide us with another strategic platform for growing our digital business, expanding our reach and broadening our services for advertisers and marketers," and both Tronc and Daily News executives said the company would maintain the quality of the paper's journalism.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]
- Martin Shkreli, ‘Pharma Bro,’ Prepares for Trial: ‘I’m So Innocent’
By STEPHANIE CLIFFORD - Thursday Jun 22, 2017
The former hedge fund manager, vilified by the public and politicians after increasing the price of a prescription drug, is facing eight counts of securities and wire fraud.